论文信息 - Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

The aim was to evaluate the efficacy of the catechol‐O‐methyltransferase inhibitor opicapone (25 and 50 mg) as adjunct therapy to levodopa in a pooled population of Parkinson's disease patients who participated in the pivotal double‐blind trials of opicapone and their 1‐year open‐label extensions.

[1] W. Poewe,et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease , 2018, Neurology.

[2] W. Poewe,et al. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial , 2017, JAMA neurology.

[3] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[4] Werner Poewe,et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial , 2016, The Lancet Neurology.

[5] C. Clarke,et al. Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[6] A. Schapira,et al. Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis , 2009, European journal of neurology.